Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Idle Evening Thoughts

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 13, 2023 8:32pm

172 Views

Post# 35783524

RE:RE:RE:Idle Evening Thoughts

Given MC's generous compensation over the past 25 years, he should have a net worth well over 10 million dollars (assuming no drug or gambling habits).

It would be small change for him to find $253,000 for exercising those options and it would be a noble gesture in a time of uncertainty for the company.

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali